Anatara Lifesciences Ltd (ASX: ANR) - Share Price
- Current share price for ANR : $0.009
Anatara Lifesciences Ltd (ANR) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is developing and commercialising innovative, evidence-based health products where there is unmet need. The Company is focused on building a pipeline of human health products with a particular focus on conditions that involve the complexity of the gastrointestinal tract.
ANR General Information +
| ASX Code | ANR |
| Website | http://www.anataralifesciences.com |
| Industry/Sector | Biotechnology |
| Market Cap ($M) | 2 |
| ANR Share Price | $0.009 |
| Day High | $0.009 |
| Day Low | $0.009 |
| Last Close | $0.009 |
| ANR Share Price Movement | - ( No change ) |
Prices as at 12:05, 1 Sep 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Anatara Lifesciences Ltd (ANR) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Anatara Lifesciences Ltd (ANR) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Anatara Lifesciences Ltd (ANR) price-sensitive announcements
ANR - Appendix 4E & Financial Report 30 June 2026
Anatara Lifesciences Ltd, an Australian company, reported its financial performance for th
Anatara Lifesciences Ltd (ANR)
18 Aug 2026 | 6:18 PM
18 Aug 2026 | 6:18 PM
ANR - Quarterly Activities/Appendix 4C Cash Flow Report
Anatara Lifesciences Ltd (ASX: ANR) has released its Appendix 4C and Quarterly Activities
Anatara Lifesciences Ltd (ANR)
31 Jul 2026 | 4:46 PM
31 Jul 2026 | 4:46 PM
ANR - Quarterly Activities/Appendix 4C Cash Flow Report
Anatara Lifesciences Ltd, a company focused on developing evidence-based health products,
Anatara Lifesciences Ltd (ANR)
29 Apr 2026 | 5:08 PM
29 Apr 2026 | 5:08 PM
ANR - Appendix 4D & Half Year Report 31 December 2025
Anatara Lifesciences Ltd reported a decrease in revenue and an improved net loss for the h
Anatara Lifesciences Ltd (ANR)
25 Feb 2026 | 1:04 PM
25 Feb 2026 | 1:04 PM
Anatara Lifesciences Ltd (ANR) Recent ASX Announcements
ANR Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2026A | -$0.93 | -$0.30 | -64.20% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2025A | -$1.95 | -$1.00 | -2.10% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$1.45 | -$1.00 | -50.30% | 0.00 | 0.00 | 0.00% | 0.0% |
ANR Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | ||
| Anatara Lifesciences Ltd (ANR) | $3M | -0.6421 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| CSL Limited (CSL) | $82,526M | 0.7309 | -0.4392 | 0.0505 | 10.6756 | 19.0360 | 18.1210 | 2.47% | 2.44% | 2.52% |
| Clinuvel Pharmaceuticals Limited (CUV) | $427M | -0.0696 | -0.0719 | 0.0242 | 12.6796 | 13.6613 | 13.3386 | 0.59% | 0.59% | 0.59% |
| Mesoblast Limited (MSB) | $3,195M | -0.4380 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Telix Pharmaceuticals Limited (TLX) | $5,318M | -1.3893 | 0.0000 | -0.9100 | 0.0000 | 148.3412 | 1,647.3684 | 0.00% | 0.00% | 0.00% |
ANR Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 3.91 | 0.00 |
| Market | 0.37 | 13.40 | 1.17 | 0.80 |
| Sector | 0.64 | 31.40 | 2.63 | 2.61 |
ANR Directors
| Name | Position | Start Date |
|---|---|---|
| Mr John Michailidis | Chief Operating Officer, Executive Director | 2 Oct 2023 |
| Dr David Lionel Brookes | Executive Chairman, Executive Director | 23 Jan 2019 |
| Mr Dirk van Dissel | Non-Executive Director | 29 Sep 2025 |
Anatara Lifesciences Ltd (ANR) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 26 Nov 2025 | BROOKES, David | Issued | Indirect Shares | 3,333,334 | $0.012 | $40,000.000 |
| 26 Nov 2025 | DISSEL, Dirk | Issued | Indirect Shares | 3,333,333 | $0.012 | $40,000.000 |
| 23 Dec 2024 | BROOKES, David | Buy | Indirect Shares | 500,000 | $0.050 | $25,000.000 |
See all changes in directors' interest & trades for Anatara Lifesciences Ltd (ANR) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
ANR Management
| Name | Position |
|---|---|
| Simon Erskine | Chief Development Officer |
| Jonathan William Lindh | Company Secretary |
ANR Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Anatara Lifesciences Ltd (ANR). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 29,000,000 (11.73%) | Robert Anthony Lederer |
| 21,607,763 (8.74%) | Ubs Nominees Pty Ltd |
ANR Calendar of Events
| Date | Event |
|---|---|
| 17 August 2027 | Report (Prelim) |
| 24 February 2027 | Report (Interim) |
| 16 October 2026 | Report (Annual) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
